A private pharmaceutical company is in the process of developing a patented drug to treat Nocturia and is expected to be the first to market in the space. With the size of the market, revenue is expected to be $20 billion at 15 cents a dose. The drug is a low dose combination of ibuprofen and acetaminophen that work synergistically to inhibit prostaglandin (PGE2) production within the COX1/2 enzymes that cause bladder irritation. As the half-life of the drug is approximately 2 hours, the extended release formula is critical to it maintaining efficiency.

Nocturia is a medical condition that causes the sufferer to excessively urinate at night. This condition effects over 10% of the population causing insomnia and sleep deprivation that can result in an increased risk of accidents and cognitive dysfunction. There are currently no drugs on the market focused on treating the problem.